Two new nitric oxide synthase inhibitors: Pyridoxal aminoguanidine and 8-quinolinecarboxylic hydrazide selectively inhibit basal but not agonist-stimulated release of nitric oxide in rat aorta

Pharmacological Research

Volumn 46, Issue 4, 2002, Pages 317-320

  Pekiner, Can ^a   Kelicen, Pelin ^a   Serdar, Uma ^a   Miwa, Ichitomo ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Aorta; Nitric oxide; Pyridoxal aminoguanidine; Rat

Indexed keywords

ACETYLCHOLINE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; N(G) METHYLARGININE; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; QUINOLINE DERIVATIVE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; 8 QUINOLINECARBOXYLIC HYDRAZIDE; ARGININE; CHEMICAL COMPOUND; HYDRAZIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PYRIDOXAL; PYRIDOXAL AMINOGUANIDINE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; IN VITRO STUDY; MALE; METABOLISM; MUSCLE RELAXATION; RAT; THORACIC AORTA; VASCULAR SMOOTH MUSCLE; WISTAR RAT; AGONIST; ANIMAL TISSUE; AORTA; AORTA CONSTRICTION; ARTERY ENDOTHELIUM; ARTERY TONE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG INHIBITION; EVALUATION; INCUBATION TIME; ISOLATED ORGAN; NONHUMAN; PRIORITY JOURNAL; STIMULUS RESPONSE; VASCULAR RING;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; ENZYME INHIBITORS; GUANIDINES; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROARGININE; OMEGA-N-METHYLARGININE; PHENYLEPHRINE; QUINOLINES; RATS; RATS, WISTAR; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0036418649     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043661802001275     Document Type: Article

References (14)

1. Furchgott RF. The role of the endothelium in the response of vascular smooth muscle to drugs. Ann Rev Pharmacol Toxicol 1984; 24: 175-97
2. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6
3. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesise nitric oxide from L-arginine. Nature 1988; 333: 664-6
4. Myers PR, Minor RL Jr, Bates JN, Harrison DG. Vasorelaxant properties of endothelium-derived relaxing factor more closely resemble S-nitrosocystein than nitric oxide. Nature 1990; 345: 161-3
5. Rees DD, Palmer RMJ, Hodson HF, Moncada S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxations. Br J Pharmacol 1989; 96: 418-24
6. G-Nitro-L-arginine (L-NOARG) a novel, arginine reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol 1990; 99: 408-12
7. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-32
8. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WMMG, Corbett JA, McDaniel ML, Williamson JR. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993; 42: 221-32
9. Griffiths MJD, Messent M, MacAllister RJ, Evans TW. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 1993; 110: 963-8
10. Taguchi T, Sugiura M, Hamada Y, Miwa I. In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate. Biochem Pharm 1998; 55: 1667-71
11. Miwa I, Tsugawa T, Koyasu K, Terada Y. Inhibition of advanced protein glycation by 8-quinolinecarboxylic hydrazide. Pharmacology 1996; 52: 314-20
12. Wu C-C, Chen S-J, Szabo C, Thiermann C, Vane JR. Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxemic shock. Br J Pharmacol 1995; 114: 166-1672
13. Yen M, Chen S-J, Wu C-C. Comparison of responses to aminoguanidine and L-NAME in the rat aorta. Clin Exp Pharm Physiol 1995; 22: 641-5
14. G-monomethyl-L-arginine. Br J Pharmacol 1993; 110: 1003-8